BACKGROUND: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is a margin negative (R0) resection. We hypothesized that a prediction rule based on pre-operative imaging would maximize the R0 resection rate while reducing non-therapeutic intervention. METHODS: The prediction rule was developed using computed tomography (CT) and endoscopic ultrasound (EUS) data from 65 patients with biopsy-proven PAC who underwent attempted resection. The rule classified patients as low or high risk for non-R0 outcome and was validated in 78 subsequent patients. RESULTS: MODEL VARIABLES WERE: any evidence of vascular involvement on CT; EUS stage and EUS size dichotomized at 2.6 cm. In the validation cohort, 77% underwent resection and 58% achieved R0 status. If only patients in the low-risk group underwent surgery, the prediction rule would have increased the resection rate to 92% and the R0 rate to 73%. The R0 rate was 40% higher in low-risk compared with high-risk patients (P < 0.001). High risk was associated with a 67% rate of non-curative surgery (unresectable disease and metastases). CONCLUSION: The prediction rule identified patients most likely to benefit from resection for PAC using pre-operative CT and EUS findings. Model predictions would have increased the R0 rate and reduced non-therapeutic interventions.
BACKGROUND: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is a margin negative (R0) resection. We hypothesized that a prediction rule based on pre-operative imaging would maximize the R0 resection rate while reducing non-therapeutic intervention. METHODS: The prediction rule was developed using computed tomography (CT) and endoscopic ultrasound (EUS) data from 65 patients with biopsy-proven PAC who underwent attempted resection. The rule classified patients as low or high risk for non-R0 outcome and was validated in 78 subsequent patients. RESULTS: MODEL VARIABLES WERE: any evidence of vascular involvement on CT; EUS stage and EUS size dichotomized at 2.6 cm. In the validation cohort, 77% underwent resection and 58% achieved R0 status. If only patients in the low-risk group underwent surgery, the prediction rule would have increased the resection rate to 92% and the R0 rate to 73%. The R0 rate was 40% higher in low-risk compared with high-risk patients (P < 0.001). High risk was associated with a 67% rate of non-curative surgery (unresectable disease and metastases). CONCLUSION: The prediction rule identified patients most likely to benefit from resection for PAC using pre-operative CT and EUS findings. Model predictions would have increased the R0 rate and reduced non-therapeutic interventions.
Authors: Rebekah R White; H Bill Xie; Marcia R Gottfried; Brian G Czito; Herbert I Hurwitz; Michael A Morse; Gerald C Blobe; Erik K Paulson; John Baillie; M Stanley Branch; Paul S Jowell; Bryan M Clary; Theodore N Pappas; Douglas S Tyler Journal: Ann Surg Oncol Date: 2005-03-03 Impact factor: 5.344
Authors: Eliza E Long; Jacques Van Dam; Stefanie Weinstein; Brooke Jeffrey; Terry Desser; Jeffrey A Norton Journal: Surg Oncol Date: 2005-08 Impact factor: 3.279
Authors: Gauri R Varadhachary; Eric P Tamm; James L Abbruzzese; Henry Q Xiong; Christopher H Crane; Huamin Wang; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Robert A Wolff Journal: Ann Surg Oncol Date: 2006-07-24 Impact factor: 5.344
Authors: Antonio Soriano; Antoni Castells; Carmen Ayuso; Juan Ramón Ayuso; Maria Teresa de Caralt; Maria Angels Ginès; Maria Isabel Real; Rosa Gilabert; Llorenç Quintó; Antoni Trilla; Faust Feu; Xavier Montanyà; Laureano Fernández-Cruz; Salvador Navarro Journal: Am J Gastroenterol Date: 2004-03 Impact factor: 10.864
Authors: Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie Abdalla; Huamin Wang; Gregg A Staerkel; Jeffrey H Lee; William A Ross; Eric P Tamm; Priya R Bhosale; Sunil Krishnan; Prajnan Das; Linus Ho; Henry Xiong; James L Abbruzzese; Douglas B Evans Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: John DeWitt; Benedict Devereaux; Melissa Chriswell; Kathleen McGreevy; Thomas Howard; Thomas F Imperiale; Donato Ciaccia; Kathleen A Lane; Dean Maglinte; Kenyon Kopecky; Julia LeBlanc; Lee McHenry; James Madura; Alex Aisen; Harvey Cramer; Oscar Cummings; Stuart Sherman Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: Brian A Boone; Nathan Bahary; Amer H Zureikat; A James Moser; Daniel P Normolle; Wen-Chi Wu; Aatur D Singhi; Phillip Bao; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Herbert J Zeh Journal: Ann Surg Oncol Date: 2015-04-24 Impact factor: 5.344
Authors: Casey A Boyd; Daniel W Branch; Kristin M Sheffield; Yimei Han; Yong-Fang Kuo; James S Goodwin; Taylor S Riall Journal: Ann Surg Oncol Date: 2012-03-27 Impact factor: 5.344
Authors: E Versteijne; J A Vogel; M G Besselink; O R C Busch; J W Wilmink; J G Daams; C H J van Eijck; B Groot Koerkamp; C R N Rasch; G van Tienhoven Journal: Br J Surg Date: 2018-04-30 Impact factor: 6.939
Authors: Samer S AlMasri; Mazen S Zenati; Annissa Desilva; Ibrahim Nassour; Brian A Boone; Aatur D Singhi; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Alessandro Paniccia; Herbert J Zeh; Amer H Zureikat; Nathan Bahary Journal: Cancer Med Date: 2021-09-24 Impact factor: 4.452
Authors: Herbert J Zeh; Nathan Bahary; Brian A Boone; Aatur D Singhi; Jennifer Lee Miller-Ocuin; Daniel P Normolle; Amer H Zureikat; Melissa E Hogg; David L Bartlett; Kenneth K Lee; Allan Tsung; J Wallis Marsh; Pranav Murthy; Daolin Tang; Natalie Seiser; Ravi K Amaravadi; Virginia Espina; Lance Liotta; Michael T Lotze Journal: Clin Cancer Res Date: 2020-03-10 Impact factor: 12.531